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The perpetual challenge in the diagnosis and manage-ment of patients with disorders of sex development
(DSD), to paraphrase the adage, is that as our circle of
knowledge in the genetic mechanisms of DSD expands, so
does the circumference of darkness surrounding it. New
technologies (comparative genomic hybridization, se-
quencing by hybridization, and next generation sequenc-
ing) are rapidly generating massive amounts of informa-
tion on the pathogenesis of DSD (1). The caveat is that
identifying a pathogenic mutation may not predict the
clinical picture because phenotype can be highly variable,
even within the same family (2). Oligogenic modulators,
developmental switches, epigenetic influences, environ-
mental stimuli, and even imbalanced cis-regulation ofmu-
tant vs. wild-type alleles when mutations are present in a
heterozygous state may also be contributing factors to the
variable expression of phenotype (3).
A major step forward in organizing the molecular and
clinical information was the recent change in nomencla-
ture and classification of DSD. In 2006, the Pediatric En-
docrine Society (formerly known as the Lawson and
Wilkins Pediatric Endocrine Society) and the European
Society for Pediatric Endocrinology consensus group de-
finedDSD as congenital conditions in which development
of chromosomal, gonadal, or anatomical sex is atypical,
and broadly classified DSD into three groups based upon
cytogenetic, hormonal, gonadal histology, and clinical
findings: 46,XY DSD, 46,XXDSD, and sex chromosome
DSD (4). The classification reflected the natural history of
the diagnostic process in which the sex chromosomes are
the usual starting point for investigations of a child with
atypical genitalia. As our genetic and endocrine under-
standing of unclassified or syndromic conditions im-
proves, the DSD classification, which continues to gain
wide acceptance across the globe (5), has the flexibility to
incorporate them into its current structure. But there is still
a long way to go to where the genetic information can be
used to predict long-term outcomes to provide personal-
ized care for the DSD patient.
In some DSD, clinical diagnosis can be confirmed by
hormonal and molecular testing. For example, in com-
plete androgen insensitivity syndrome there is an 80–
90% chance that a 46,XY infant with normal female
genitalia and normal testosterone synthesis will have a
mutation in androgen receptor gene (6). Similarly, the
majority of 46,XX presenting with virilized genitalia
will have congenital adrenal hyperplasia with a muta-
tion in CYP21A2 where genotype-phenotype correla-
tions are excellent (7).
In cases of XY DSD with partially virilized genitalia,
a molecular diagnosis has been relatively elusive so that
diagnosis is guided by a thorough clinical, biochemical,
and anatomical evaluation of the affected infant. For
instance, only about 20% of these cases associated with
normal androgen synthesis will have a mutation in the
androgen receptor gene (6).
Discordance between molecular changes and func-
tional in vitro transactivation studies complicate even fur-
ther the efforts for attributing the particular DSD pheno-
type to the identified gene change. Furthermore, such
functional studies continue to remain in the realms of re-
search laboratories, and their large-scale clinical utility
remains unclear. The recent identification of mutations
associated with DSD in a poorly characterizedMAPK sig-
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naling pathway (8) suggests that theremay be a number of
other genes that may remain unidentified.
In this issue of the JCEM, the study by Camats et al. (9)
highlights the perpetual challenges that are faced by the
DSD classification as well as our understanding of the
genetic etiology of DSD. The investigators detected and
characterized 10 novel heterozygote NR5A1 mutations
froma groupof 10046,XYDSDand twoprimary ovarian
insufficiency patients from centers in Spain, Switzerland,
and Turkey. Through an international collaboration, the
authors found high variability in the clinical, biochemical,
histological, genetic, and functional characteristics of the
10 novelNR5A1mutations. Although the genotype-phe-
notype correlation remains elusive, the study adds to the
accumulating body of evidence that approximately 10%
of XY DSD patients will have a mutation in NR5A1 and
highlights the importance of collaborative efforts in build-
ing our knowledge base of DSD.
The Camats et al. study (9) also raises the issue that
some of the phenotypic variability may be a manifesta-
tion of time-dependent deterioration of gonadal tissue
and/or steroid secretion. This is an important phenom-
enon in DSD, where the manifestation of the gene mu-
tation may vary depending on the age of the patient, as
has been seen in other defects of testosterone synthesis
and/or metabolism caused by StAR, SRD5A2, or
CYP17A1 gene mutations.
To be able to take a critical step forward and begin
better utilization of the information provided in this and
other studies, careful collection of clinical data that de-
scribe the phenotype at diagnosis as well as at a later stage
remains a critical cornerstone for understanding etiology
and long-term outcome. For these rare conditions, these
data need to be serially collected in a standardizedmethod
and should ideally include a structured description of the
genitalia and gonads, the endocrine biochemistry, psycho-
logical and psychosocial development, and medical and
surgical therapeutic intervention.
However, to date the tools that have been available to
collect these data have been very variable, have lacked
uniformity, and have not been developed specifically for
DSD.The2006ConsensusWorkshoponDSDstressed the
need for creating and maintaining databases that can fa-
cilitate standardized collection of data that can cross-talk
across geographical boundaries and facilitate interna-
tional collaboration (5). An international web-based reg-
istry, the I-DSD Registry (www.i-dsd.org), has now been
in operation for over 4 yr and has encouraged the devel-
opment ofmulticenter projects as well as the development
of other registries (10). It is now important that these reg-
istries continue to collect standardized uniform data so
that they can cross-talk in the future. In addition to re-
search, these registries have the potential to act as a patient
management tool and can also facilitate the development
of a professional and patient network.
The need for collecting standardized information
and involving the clinician in this exercise is now much
greater as the output from genetic analysis increases.
Because increasing numbers of people with syndromal
DSD are undergoing analysis using array comparative
genomic hybridization and next generation sequencing,
more pathogenic rearrangements are being reported,
and whereas they may reveal unique insights into the
mechanism of gonadal development, they may also
highlight the involvement of other coexisting disease
(1). In patients with disorders of gonadal development,
small deletions or duplications that are likely to be caus-
ative of the condition can be found in 25% of cases where
other organ systems are affected, whereas they are only
found in 6% of cases where only testis development was
affected (11). With the reducing costs of next generation
sequencing, exomeandcomplete genome sequencingoffer
much richer possibilities for understanding disease. Nev-
ertheless, the introduction of expanded genetic testing is
not without its own risk, and there is a need to develop a
clinical infrastructure that can cope with the increased
level of genetic information that will be available in the
future.The clinical validity and relevanceof the results can
only be judged after thorough evaluation of the clinical
features of the case. Recent guidance issued in the United
Kingdom has also called for greater involvement of the
clinical geneticist in themanagementof this information in
a multidisciplinary clinical setting (12). In addition to
complex genetic analysis, recent technological advances in
the field of steroid analysiswill lead to the identification of
new enzymatic causes ofDSD (13).However, this analysis
will also yield a large amount of information that will
require bioinformatic analysis. These specialist techniques
shall only be available in a handful of centers and thus
require the clinical and scientific community to increase
their ability to work as a network.
Finally, future research initiatives should incorporate a
move toward a greater understanding of how genetic
knowledge in DSD affects the quality of life of the patient
and the family. It is generally believed that the knowledge
of a genetic cause of DSD helps with explaining the con-
dition to the family and may help with genetic counseling
and discussing future risks. Although this may be clear
from the point of view of a condition such as congenital
adrenal hyperplasia, there is little published evidence that
the possession of genetic data in cases of XY DSD char-
acterized by partial virilization alters the long-term qual-
ity-of-life outcomes.
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